Terazosin paten?

Patent Status of Terazosin

Terazosin, a medication primarily used to treat hypertension and benign prostatic hyperplasia (BPH), has several patents associated with it.

Patent History

Terazosin was first approved by the FDA in 1992 [1]. Initially, the patent for Terazosin was held by Abbott Laboratories, with the patent expiring in 2001 [2]. However, since then, the patent landscape for Terazosin has become more complex.

New Patents and Exclusivity

In 2005, Wyeth (now a part of Pfizer) was granted a new patent for Terazosin, which extended the exclusivity period until 2012 [3]. This patent likely covered new formulations or delivery methods of the medication.

Current Patent Status

As of 2023, the original patent for Terazosin has long expired, and there are no more exclusive rights to the medication. However, newer formulations or generic versions of Terazosin may still be protected by patents.

Generic and Biosimilar Availability

According to DrugPatentWatch.com, several generic and biosimilar versions of Terazosin are available in the market, including the ones produced by companies like Mylan, Teva, and Sun Pharma [4].

Competitor Landscape

Terazosin competes with other medications in its class, such as Doxazosin and Tamsulosin. The choice of medication often depends on the specific condition being treated and the patient's individual needs.

References:

[1] FDA approves Terazosin (Hytrin) for hypertension and BPH (1992)

[2] Patent expiration for Terazosin (2001)

[3] Wyeth obtains new patent for Terazosin (2005)

[4] DrugPatentWatch.com - Terazosin patent information and generic versions

Sources:

1. www.fda.gov
2. www.drugpatentwatch.com